Lv41
486 积分 2025-03-29 加入
Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer
28天前
已完结
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters
1个月前
已完结
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
1个月前
已完结
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
1个月前
已完结
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
1个月前
已完结
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
1个月前
已完结
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
1个月前
已完结
Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
1个月前
已完结
Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer
1个月前
已完结
Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
1个月前
已完结
皖公网安备34019202002308
